AYTU BIOPHARMA, INC Finance Lease, Principal Payments
AYTU BIOPHARMA, INC (AYTU) reported Finance Lease, Principal Payments of $0 for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-09-22
- AYTU BIOPHARMA, INC finance lease, principal payments for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC finance lease, principal payments for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC finance lease, principal payments for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC finance lease, principal payments for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC finance lease, principal payments for fiscal 2026 was $0.00.
- AYTU BIOPHARMA, INC finance lease, principal payments for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- AYTU BIOPHARMA, INC finance lease, principal payments for fiscal 2024 was $85.00K, a 11.46% decline from fiscal 2023.
- AYTU BIOPHARMA, INC finance lease, principal payments for fiscal 2023 was $96.00K, a 5.88% decline from fiscal 2022.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-K · filed 2026-09-22 | |||
| 2025-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $0.00 10-K · filed 2026-09-22 |
| 2025-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-05-14 | $0.00 10-Q · filed 2025-05-14 | $16.00K derived: sum of 4 quarters · filed 2025-09-23 |
| 2024-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $0.00 10-Q · filed 2025-02-12 | $16.00K derived: sum of 3 quarters · filed 2025-09-23 | $39.00K derived: sum of 4 quarters · filed 2025-09-23 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | $16.00K derived: sum of 2 quarters · filed 2025-09-23 | $39.00K derived: sum of 3 quarters · filed 2025-09-23 | $62.00K derived: sum of 4 quarters · filed 2025-09-23 |
| 2024-06-30 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $39.00K derived: sum of 2 quarters · filed 2025-09-23 | $62.00K derived: sum of 3 quarters · filed 2025-09-23 | $85.00K 10-K · filed 2025-09-23 |
| 2024-03-31 | $23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14 | $46.00K derived: sum of 2 quarters · filed 2025-05-14 | $69.00K 10-Q · filed 2025-05-14 | $92.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $46.00K 10-Q · filed 2025-02-12 | $69.00K derived: sum of 3 quarters · filed 2025-02-12 | $90.00K derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-09-30 | $23.00K 10-Q · filed 2024-11-13 | $46.00K derived: sum of 2 quarters · filed 2024-11-13 | $67.00K derived: sum of 3 quarters · filed 2024-11-13 | $92.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $44.00K derived: sum of 2 quarters · filed 2024-09-26 | $69.00K derived: sum of 3 quarters · filed 2024-09-26 | $96.00K 10-K · filed 2024-09-26 |
| 2023-03-31 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $46.00K derived: sum of 2 quarters · filed 2024-05-15 | $73.00K 10-Q · filed 2024-05-15 | $99.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | $52.00K 10-Q · filed 2024-02-14 | $78.00K derived: sum of 3 quarters · filed 2024-02-14 | $104.00K derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-09-30 | $27.00K 10-Q · filed 2023-11-14 | $53.00K derived: sum of 2 quarters · filed 2023-11-14 | $79.00K derived: sum of 3 quarters · filed 2023-11-14 | $104.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $52.00K derived: sum of 2 quarters · filed 2023-10-12 | $77.00K derived: sum of 3 quarters · filed 2023-10-12 | $102.00K 10-K · filed 2023-10-12 |
| 2022-03-31 | $26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | $51.00K derived: sum of 2 quarters · filed 2023-05-11 | $76.00K 10-Q · filed 2023-05-11 | $98.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $25.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-02-21 | $50.00K 10-Q · filed 2023-02-21 | $72.00K derived: sum of 3 quarters · filed 2023-02-21 | |
| 2021-09-30 | $25.00K 10-Q/A · filed 2023-02-21 | $47.00K derived: sum of 2 quarters · filed 2023-02-21 | ||
| 2021-06-30 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $25.00K 10-K · filed 2022-09-27 | ||
| 2021-03-31 | $3.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |